These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 32940075)

  • 1. Possibility of detecting intraductal papillary mucinous neoplasms using metabolite biomarkers for pancreatic cancer.
    Nakano R; Nishiumi S; Kobayashi T; Ikegawa T; Kodama Y; Yoshida M
    Biomark Med; 2020 Jul; 14(11):1009-1020. PubMed ID: 32940075
    [No Abstract]   [Full Text] [Related]  

  • 2. Pancreatic Fluid Interleukin-1β Complements Prostaglandin E2 and Serum Carbohydrate Antigen 19-9 in Prediction of Intraductal Papillary Mucinous Neoplasm Dysplasia.
    Simpson RE; Yip-Schneider MT; Flick KF; Wu H; Colgate CL; Schmidt CM
    Pancreas; 2019 Sep; 48(8):1026-1031. PubMed ID: 31404023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of Serum Biomarker Panels for the Early Detection of Pancreatic Cancer.
    Song J; Sokoll LJ; Pasay JJ; Rubin AL; Li H; Bach DM; Chan DW; Zhang Z
    Cancer Epidemiol Biomarkers Prev; 2019 Jan; 28(1):174-182. PubMed ID: 30333219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urinary microRNA-210-3p as a novel and non-invasive biomarker for the detection of pancreatic cancer, including intraductal papillary mucinous carcinoma.
    Imamura T; Komatsu S; Nishibeppu K; Kiuchi J; Ohashi T; Konishi H; Shiozaki A; Yamamoto Y; Moriumura R; Ikoma H; Ochiai T; Otsuji E
    BMC Cancer; 2024 Jul; 24(1):907. PubMed ID: 39069624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum Metabolomic Profiles for Human Pancreatic Cancer Discrimination.
    Itoi T; Sugimoto M; Umeda J; Sofuni A; Tsuchiya T; Tsuji S; Tanaka R; Tonozuka R; Honjo M; Moriyasu F; Kasuya K; Nagakawa Y; Abe Y; Takano K; Kawachi S; Shimazu M; Soga T; Tomita M; Sunamura M
    Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28375170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Malignant potential in pancreatic neoplasm; new insights provided by circulating miR-223 in plasma.
    Komatsu S; Ichikawa D; Miyamae M; Kawaguchi T; Morimura R; Hirajima S; Okajima W; Ohashi T; Imamura T; Konishi H; Shiozaki A; Ikoma H; Okamoto K; Taniguchi H; Otsuji E
    Expert Opin Biol Ther; 2015 Jun; 15(6):773-85. PubMed ID: 25819175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extracellular Vesicle Analysis Allows for Identification of Invasive IPMN.
    Yang KS; Ciprani D; O'Shea A; Liss AS; Yang R; Fletcher-Mercaldo S; Mino-Kenudson M; Fernández-Del Castillo C; Weissleder R
    Gastroenterology; 2021 Mar; 160(4):1345-1358.e11. PubMed ID: 33301777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Diagnostic efficacy for predicting intraductal papillary mucinous neoplasms of the pancreas with high grade dysplasia or invasive carcinoma based on the surgery indications in different guidelines].
    Li B; Guo SW; Shi XH; Shen S; Zhang GX; Gao SZ; Pan YQ; Xu XF; Jin G
    Zhonghua Wai Ke Za Zhi; 2021 May; 59(5):359-365. PubMed ID: 33915626
    [No Abstract]   [Full Text] [Related]  

  • 9. Pancreatic cyst fluid and serum mucin levels predict dysplasia in intraductal papillary mucinous neoplasms of the pancreas.
    Maker AV; Katabi N; Gonen M; DeMatteo RP; D'Angelica MI; Fong Y; Jarnagin WR; Brennan MF; Allen PJ
    Ann Surg Oncol; 2011 Jan; 18(1):199-206. PubMed ID: 20717734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin-like growth factor II messenger RNA-binding protein-3 is a valuable diagnostic and prognostic marker of intraductal papillary mucinous neoplasm.
    Morimatsu K; Aishima S; Yamamoto H; Hayashi A; Nakata K; Oda Y; Shindo K; Fujino M; Tanaka M; Oda Y
    Hum Pathol; 2013 Sep; 44(9):1714-21. PubMed ID: 23597774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-density and targeted glycoproteomic profiling of serum proteins in pancreatic cancer and intraductal papillary mucinous neoplasm.
    Aronsson L; Andersson R; Bauden M; Andersson B; Bygott T; Ansari D
    Scand J Gastroenterol; 2018 Dec; 53(12):1597-1603. PubMed ID: 30509115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Value of adding GNAS testing to pancreatic cyst fluid KRAS and carcinoembryonic antigen analysis for the diagnosis of intraductal papillary mucinous neoplasms.
    Kadayifci A; Atar M; Wang JL; Forcione DG; Casey BW; Pitman MB; Brugge WR
    Dig Endosc; 2017 Jan; 29(1):111-117. PubMed ID: 27514845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical implication of serum carcinoembryonic antigen and carbohydrate antigen 19-9 for the prediction of malignancy in intraductal papillary mucinous neoplasm of pancreas.
    Kim JR; Jang JY; Kang MJ; Park T; Lee SY; Jung W; Chang J; Shin Y; Han Y; Kim SW
    J Hepatobiliary Pancreat Sci; 2015 Sep; 22(9):699-707. PubMed ID: 26178866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. mAb Das-1 is specific for high-risk and malignant intraductal papillary mucinous neoplasm (IPMN).
    Das KK; Xiao H; Geng X; Fernandez-Del-Castillo C; Morales-Oyarvide V; Daglilar E; Forcione DG; Bounds BC; Brugge WR; Pitman MB; Mino-Kenudson M; Das KM
    Gut; 2014 Oct; 63(10):1626-34. PubMed ID: 24277729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blood-Based Diagnosis and Risk Stratification of Patients with Pancreatic Intraductal Papillary Mucinous Neoplasm (IPMN).
    Zhang C; Al-Shaheri FN; Alhamdani MSS; Bauer AS; Hoheisel JD; Schenk M; Hinz U; Goedecke P; Al-Halabi K; Büchler MW; Giese NA; Hackert T; Roth S
    Clin Cancer Res; 2023 Apr; 29(8):1535-1545. PubMed ID: 36516200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Macrophage inhibitory cytokine-1/growth differentiation factor-15 in premalignant and neoplastic tumours in a high-risk pancreatic cancer cohort.
    O'Neill RS; Emmanuel S; Williams D; Stoita A
    World J Gastroenterol; 2020 Apr; 26(14):1660-1673. PubMed ID: 32327914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of Small Proteins and Peptides in the Differentiation of Patients with Intraductal Mucinous Neoplasms of the Pancreas, Chronic Pancreatitis and Pancreatic Adenocarcinoma.
    Fania C; Pezzilli R; Melzi d'Eril G; Gelfi C; Barassi A
    Dig Dis Sci; 2018 Apr; 63(4):920-933. PubMed ID: 29417328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Updates and Critical Evaluation on Novel Biomarkers for the Malignant Progression of Intraductal Papillary Mucinous Neoplasms of the Pancreas.
    Moris D; Damaskos C; Spartalis E; Papalampros A; Vernadakis S; Dimitroulis D; Griniatsos J; Felekouras E; Nikiteas N
    Anticancer Res; 2017 May; 37(5):2185-2194. PubMed ID: 28476781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biomarker Development for Intraductal Papillary Mucinous Neoplasms Using Multiple Reaction Monitoring Mass Spectrometry.
    Kim Y; Kang M; Han D; Kim H; Lee K; Kim SW; Kim Y; Park T; Jang JY; Kim Y
    J Proteome Res; 2016 Jan; 15(1):100-13. PubMed ID: 26561977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytology adds value to monoclonal antibody Das-1 testing for detection of high-risk pancreatic cysts.
    Heidarian A; Das KK; Mino-Kenudson M; Fernandez-Del Castillo C; Pitman MB
    J Am Soc Cytopathol; 2021; 10(3):249-254. PubMed ID: 33541830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.